Analysts: Endo Health Solutions Inc (ENDP.OQ)
ENDP.OQ on NASDAQ Stock Exchange Global Select Market
39.04USD
11:29am EDT
39.04USD
11:29am EDT
Price Change (% chg)
$-0.01 (-0.03%)
$-0.01 (-0.03%)
Prev Close
$39.05
$39.05
Open
$39.01
$39.01
Day's High
$39.10
$39.10
Day's Low
$38.66
$38.66
Volume
65,086
65,086
Avg. Vol
526,816
526,816
52-wk High
$39.90
$39.90
52-wk Low
$25.01
$25.01
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Hold | 1.08 | December | 2 Aug 2013 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 6 | 6 | 5 | 7 |
| (2) OUTPERFORM | 2 | 2 | 2 | 2 |
| (3) HOLD | 6 | 5 | 7 | 8 |
| (4) UNDERPERFORM | 5 | 5 | 4 | 3 |
| (5) SELL | 1 | 1 | 1 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.65 | 2.63 | 2.68 | 2.35 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 17 | 682.13 | 727.50 | 659.30 | 860.76 |
| Quarter Ending Dec-13 | 17 | 632.81 | 658.90 | 608.90 | 824.11 |
| Year Ending Dec-13 | 21 | 2,744.48 | 2,812.52 | 2,677.10 | 3,334.60 |
| Year Ending Dec-14 | 21 | 2,382.41 | 2,520.80 | 2,256.23 | 3,215.20 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | 19 | 1.08 | 1.33 | 0.94 | 1.54 |
| Quarter Ending Dec-13 | 19 | 1.01 | 1.16 | 0.75 | 1.28 |
| Year Ending Dec-13 | 20 | 4.32 | 4.82 | 4.10 | 5.54 |
| Year Ending Dec-14 | 21 | 3.74 | 4.48 | 3.05 | 5.01 |
| LT Growth Rate (%) | 7 | 2.47 | 14.00 | -12.00 | 8.43 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-13 | 736.15 | 708.52 | 27.63 | 3.75 |
| Quarter Ending Dec-12 | 807.98 | 801.06 | 6.92 | 0.86 |
| Quarter Ending Sep-12 | 788.28 | 750.48 | 37.80 | 4.80 |
| Quarter Ending Jun-12 | 775.20 | 785.19 | 9.99 | 1.29 |
| Quarter Ending Mar-12 | 702.47 | 690.63 | 11.84 | 1.69 |
| Earnings (per share) | ||||
| Quarter Ending Mar-13 | 1.07 | 1.09 | 0.02 | 1.71 |
| Quarter Ending Dec-12 | 1.55 | 1.62 | 0.07 | 4.40 |
| Quarter Ending Sep-12 | 1.25 | 1.28 | 0.03 | 2.01 |
| Quarter Ending Jun-12 | 1.19 | 1.27 | 0.08 | 7.13 |
| Quarter Ending Mar-12 | 0.87 | 0.87 | 0.00 | 0.47 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 682.13 | 681.55 | 681.64 | 701.04 | 860.76 |
| Quarter Ending Dec-13 | 632.81 | 631.82 | 631.70 | 657.03 | 824.11 |
| Year Ending Dec-13 | 2,744.48 | 2,743.93 | 2,742.41 | 2,802.03 | 3,334.60 |
| Year Ending Dec-14 | 2,382.41 | 2,377.18 | 2,385.42 | 2,470.56 | 3,215.20 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | 1.08 | 1.09 | 1.09 | 1.06 | 1.54 |
| Quarter Ending Dec-13 | 1.01 | 1.00 | 1.00 | 0.95 | 1.28 |
| Quarter Ending Dec-13 | 4.32 | 4.33 | 4.31 | 4.26 | 5.54 |
| Quarter Ending Dec-14 | 3.74 | 3.73 | 3.77 | 3.57 | 5.01 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-13 | 1 | 0 | 2 | 2 |
| Quarter Ending Dec-13 | 1 | 0 | 2 | 2 |
| Year Ending Dec-13 | 1 | 0 | 5 | 0 |
| Year Ending Dec-14 | 1 | 0 | 1 | 3 |
| Earnings | ||||
| Quarter Ending Sep-13 | 0 | 1 | 1 | 3 |
| Quarter Ending Dec-13 | 1 | 0 | 3 | 1 |
| Year Ending Dec-13 | 0 | 1 | 3 | 1 |
| Year Ending Dec-14 | 1 | 0 | 1 | 3 |
- DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan
- Endo Health to slash 15 percent jobs, looks to sell some assets
- UPDATE 1-Endo Health to slash 15 pct jobs, looks to sell some assets
- Endo Health to cut 15 pct jobs, explore options for two units
- FDA denies approval to Endo's testosterone drug again
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Earnings vs.
Estimates